A Randomized, Double-Blind, Phase 4 Study to Evaluate the Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Patients Post Bariatric Surgery
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 11 Apr 2016
At a glance
- Drugs Naltrexone/bupropion (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Takeda
- 07 Apr 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 07 Jan 2016 Planned initiation date changed from 1 Dec 2015 to 1 Feb 2016, according to ClinicalTrials.gov record.
- 01 Dec 2015 Planned initiation date changed from 1 Nov 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov.